Your session is about to expire
← Back to Search
Durvalumab + Radiation for Lung Cancer
Study Summary
This trial will compare the effectiveness of durvalumab + SBRT to SBRT alone in treating early-stage NSCLC.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 80 Patients • NCT03015129Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have received treatments before.I have had cancer spread to the lining of my brain and spinal cord.I will not donate blood while on durvalumab treatment.You weigh more than 30 kilograms.I've had chest radiation that prevents targeted radiation for my current tumor.My lung cancer is in an early stage (I to IIIA) without spread to nearby nodes.I have not received any live vaccines in the last 4 weeks and won't while on the trial, except for inactivated vaccines.I am fully active or able to carry out light work.I cannot have radiotherapy due to certain health reasons.My cancer has a specific change in the EGFR or ALK gene.I cannot or do not want to have surgery for my condition as advised by a specialist.I don't have lasting side effects from cancer treatment, except for hair loss or skin changes.Based on a specific test, it is predicted that there is a high chance of the disease getting worse within 2 years.I can sign and will follow the study's rules as explained in the consent form.I have or had an autoimmune or inflammatory disorder.You have to have a standard biopsy confirming non-small cell lung cancer. There is no need for an extra biopsy for this study.I am 18 years old or older.I am a candidate for targeted radiation therapy.You are expected to live for at least 12 more weeks.I haven't had major surgery in the last 28 days, except for minor surgeries to relieve symptoms.You have a history of a weak immune system that has been active.I am not pregnant, breastfeeding, and willing to use effective birth control during and up to 90 days after treatment.I have a connective tissue disorder or lung scarring.My organs and bone marrow are functioning well.
- Group 1: Participants with Early-stage Non-Small Cell Lung Cancer
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there other examples in the medical literature of Durvalumab's effects?
"City of Hope was the first institution to study durvalumab back in 2010 and, since then, 123 completed studies have been conducted. As of now, there are 338 active trials recruiting patients with a majority taking place in Middletown, New jersey."
In how many different medical clinics is this clinical study being conducted?
"To make things more convenient for participants, the trial is being conducted at 9 sites close to major cities. The locations are Middletown, New york and Commack along with other locations within a commutable distance."
Are we still taking people in for this research project?
"The clinical trial, which is hosted on clinicaltrials.gov, is currently recruiting patients. The study was posted on 1/27/2021 and updated on 10/12/2022. They are looking for a total of 40 participants that will be spread out across 9 locations."
What is the most popular reason that doctors prescribe Durvalumab?
"Durvalumab is a common treatment for unresectable stage iii non-small cell lung cancer. Durvalumab has also shown to be effective against metastatic ureter urothelial carcinoma, and advance directives."
What is the official government stance on Durvalumab?
"While Phase 2 trials don't have the same level of data to support efficacy, there is enough evidence of safety to give Durvalumab a score of 2."
How many people can enroll in this clinical trial?
"That is correct. The study, which was created on 1/27/2021 and last updated on 10/12/2022, is still looking for enrollees. In total, they need 40 patients from 9 different locations."
Share this study with friends
Copy Link
Messenger